Ceryx Medical Initiates First-In-Human Study of the Cysoni™ RSA Pacemaker
Ceryx Medical notes the RSA-Pace study will enroll up to 60 patients at centers in the UK, New Zealand and Australia.
Ceryx Medical notes the RSA-Pace study will enroll up to 60 patients at centers in the UK, New Zealand and Australia.